Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10901039 | Cancer Letters | 2016 | 11 Pages |
Abstract
Angiogenesis is sustained by classical and non-classical proangiogenic factors (PFs) acting in tumor microenvironment and these factors are also potential targets of antiangiogenic therapies. All PFs induce the overexpression of several signaling pathways that lead to migration and proliferation of endothelial cells contributing to tumor angiogenesis and survival of cancer cells. In this review, we have analyzed each PF with its specific receptor/s and we have summarized the available antiangiogenic drugs (e.g. monoclonal antibodies) targeting these PFs, some of these agents have already been approved, others are currently in development for the treatment of several human malignancies.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ilaria Marech, Christian Leporini, Michele Ammendola, Mariangela Porcelli, Cosmo Damiano Gadaleta, Emilio Russo, Giovambattista De Sarro, Girolamo Ranieri,